You are here: Industry Insights > Novartis

News List

Banner Alzheimer's Institute, Novartis, and Amgen Expand Collaboration in Pioneering Alzheimer's Pre biospectrumasia
November 09, 2017
The API Generation Program is the first to incorporate both genetic testing and counselling in addition to amyloid disclosure education into the study screening process.
With new FDA nod, Roche's Alecensa set to challenge Pfizer, Novartis in first-line lung cancer fiercepharma
November 08, 2017
Roche's lung cancer drug Alecensa had been relegated to patients who'd failed on treatment with one of its rivals, but a new FDA nod is changing all that.
Novartis, Amgen, BAI start new Alzheimer’s prevention Trial worldpharmanews
November 06, 2017
Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Initiative (API) Generation Study 2
Novartis, Amgen and Banner aim for Alzheimer’s prevention with new BACE trials fiercebiotech
November 03, 2017
We’ve seen it time and time again over the past 15 years from a particularly cruel disease that robs people of their memories and eventually kills them.
Novartis to acquire radio-pharma for $3.9B biospectrumasia
November 02, 2017
AAA had sales of $78 million in the first half of 2017, with a net loss from continuing operations of $24.2 million.
Novartis announces the planned acquisition of AAA to strengthen oncology programs worldpharmanews
October 31, 2017
Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions.
Novartis Q3: Jimenez talks up Alcon, Gleevec takes generic hammering pharmafile
October 25, 2017
Novartis released its Q3 financials and, despite Gleevec dipping significantly due to generic competition, still managed to report sales of $12.4 billion, up 2% on the previous year’s results.
Breakthrough badge for Novartis’ skin cancer combo pharmatimes
October 25, 2017
A targeted combination therapy being developed by Novartis as adjuvant treatment for patients with a certain type of melanoma has been assigned breakthrough designation in the US.
Novartis to shut down its US generics plant under pricing pressure pharmafile
October 19, 2017
Novartis has announced that it's going to close its US generics manufacturing plant in Broomfield, Colorado, a change that will resulted in a cut of 450 jobs over two-year long.
Revolade shows long-term disease control for immune thrombocytopenia europeanpharmaceuticalreview
October 19, 2017
Novartis has announced long-term study results supporting the positive safety and efficacy of Revolade in adults with chronic/persistent immune thrombocytopenia…

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page